A Review of the Cost Effectiveness of Transcatheter Aortic Valve Replacement (TAVR) Versus Surgical Aortic Valve Replacement (SAVR)

The cost of transcatheter aortic valve replacement (TAVR) has been studied in the context of high-risk or specific comorbidity populations; this paper provides a comprehensive overview of broader patient populations’ outcomes and costs with TAVR in comparison to surgical aortic valve replacement (SA...

Full description

Saved in:
Bibliographic Details
Published in:Curēus (Palo Alto, CA) CA), 2023-10, Vol.15 (10), p.e46535-e46535
Main Authors: Kermanshahchi, Jonathan, Thind, Birpartap, Davoodpour, Gabriel, Hirsch, Megan, Chen, Jeff, Reddy, Akshay J, Chan, Evan, YU, Zeyu, Javidi, Daryoush
Format: Article
Language:English
Subjects:
Aortic stenosis
Cardiac/Thoracic/Vascular Surgery
Cardiology
Cost analysis
Length of stay
Mortality
Patients
Surgical techniques
Trends
Veins & arteries
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The cost of transcatheter aortic valve replacement (TAVR) has been studied in the context of high-risk or specific comorbidity populations; this paper provides a comprehensive overview of broader patient populations’ outcomes and costs with TAVR in comparison to surgical aortic valve replacement (SAVR). In the past, SAVR had been the more cost-effective option than TAVR, but in recent years, TAVR has been becoming more cost-effective.Though the cost of TAVR can vary due to several factors the major focus of this review will focus on the surgical technique, medicare reimbursements, insertion point, and varying risk populations. In conclusion, the price of TAVR is declining as more cost-efficient valves arrive on the market. Climbing healthcare costs play a significant role in clinical decisions when deciding on which procedures are most cost-effective for the patient and healthcare system. The declining price of TAVR could lead to the preference of TAVR over SAVR for both low-risk and high-risk aortic stenosis patients.
ISSN:2168-8184
2168-8184
DOI:10.7759/cureus.46535